Delisting Determination,The Nasdaq Stock Market, LLC,
July 10, 2009, XTL Biopharmaceuticals Ltd. The Nasdaq Stock
Market, Inc. (the Exchange) has determined to remove from
listing the common stock of XTL Biopharmaceuticals Ltd.
(the Company), effective at the opening of the
trading session on July 20, 2009. Based on a review of
the information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for
listing on the Exchange pursuant to Listing Rules
5100 and 5550(b)(1). The Company was notified of the
Staffs determination on January 27, 2009. The Company
requested a review of the Staffs determination before the
Listing Qualifications Hearings Panel. Upon review of the
information provided by the Company, the Panel determined
that the Company did not qualify for inclusion on the
Exchange based on its failure to comply with the following
Listing Rules: 5100 and 5550(b)(1). The Company was notified
of the Panels decision on April 15, 2009 and
trading in the Companys securities was suspended on
April 17, 2009. The Company did not request a review
of the Panels decision by the Nasdaq Listing and Hearing
Review Council. The Listing Council did not call the
matter for review. The Panels Determination to delist
the Company became final on June 1, 2009.